Conquering Cancer Close to Home
Visit Our Main Site Request Appointment

Current Trial Listing

Condition Trial Name Sponsor
Solid Tumors 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc.
Non-Small Cell Lung Cancer AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC AbbVie
Non-Small Cell Lung Cancer ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor OSE Immunotherapeutics
Breast Cancer ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer Gilead Sciences, Inc.
Cachexia AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia AVEO Pharmaceuticals, Inc.
Colon Cancer AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer GlaxoSmithKline
Breast Cancer BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer BriaCell Therapeutics Corporation
Non-Small Cell Lung Cancer COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment Janssen Research & Development, LLC
Non-Small Cell Lung Cancer CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform Elephas Biosciences Corporation
Central Nervous System Cancer F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics
Breast Cancer First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer Regor Pharmaceuticals Inc.
Colorectal Cancer INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer Hoffmann-La Roche
Breast Cancer MoonROSE: CDK2/4/6 Inhibitor GDC-4198 in Combination with Giredestrant for Patients with ER+, HER2- Metastatic Breast Cancer After Treatment with a CDK4/6 Inhibitor Genentech, Inc.
Colorectal Cancer OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC
Colorectal Cancer OrigAMI-3: Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC
Advanced Solid tumors Phase 1 Study of SGN-B6A in Advanced Solid Tumors Seagen Inc.
Chronic Myeloid Leukemia POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML Ascentage Pharma Group Inc.
Solid Tumors or Multiple Myeloma QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Nammi Therapeutics Inc
Cancer Diagnosis [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Solid Tumors [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics
Solid Tumors [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Solid Tumors [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc.

Need More Information?

Our team is here to help answer your questions and guide you through your options.